Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Allogeneic iPS cell-derived cardiac spheroids
Applicable field (uses covered by this announcement)
Regenerative medicine for severe heart failure
Relationship between the counterparty and the company
Heartseed Inc.219A
Relationship with the Company
Licensing authority to which the application was submitted
CounterpartyTokyo Metropolitan Government
Impact on Business Performance
No revision has been made to the earnings forecast for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Allogeneic iPS cell-derived cardiac spheroids |
| Counterparty | Tokyo Metropolitan Government |
| Relationship with the Company | Licensing authority to which the application was submitted |
| Applicable area | Regenerative medicine for severe heart failure |
| Impact on Business Performance | No revision has been made to the earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (13)
Counterparty overviewContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish systems compliant with Good Quality Practice (GQP) and Good Vigilance Practice (GVP), in anticipation of future applications for manufacturing and marketing approval and commercialization and launch in Japan.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.